Method of producing the polypeptide for treating virus-induced cancer
AssigneePheromonicin Biotech, Ltd.
InventorXiao-Qing Qiu
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of producing the polypeptides that are capable of killing cells. The polypeptides comprise a targeting agent covalently attached to a channel-forming moiety. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is a reconstructed antibody mimetic derived from monoclonal antibody variants against Epstein-Barr virus gp350/220.
Claims19
A method of producing a fusion polypeptide for treating a cell proliferative disorder in a mammal, the fusion polypeptide comprising a cancer cell targeting agent that targets mammalian cancer cells covalently attached to a channel-forming moiety so as to have an anti-cell proliferative activity on mammalian cancer cells, wherein said channel forming moiety is a channel-forming peptide or channel-forming fragment thereof that is selected from the group consisting of an E1, Ia, Ib, A, K or N colicin, the method comprising:
- culturing a host cell such that said fusion polypeptide is produced,
- wherein said host cell comprises a vector comprising a nucleic acid molecule encoding the fusion polypeptide.
A method of producing a fusion polypeptide for treatment of a cell proliferative disorder in a mammal cell, the fusion polypeptide comprising a cancer cell targeting moiety being a reconstructed antibody mimetic derived from an engineered antibody against Epstein-Barr virus gp350/220 envelope glycoprotein complex that targets mammalian cancer cells and a channel-forming domain of colicin so as have an anti-cell proliferative activity on cancer cells, the method comprising:
- culturing a host cell such that said fusion polypeptide is produced,
- wherein said host cell comprises a vector that comprises a nucleic acid molecule encoding the fusion polypeptide.
Dependencies are inferred from the claim text.